Medovex Corporation Announces Successful Largest Living Tissue Population Test to Date

Medovex Corp. has conducted a successful live tissue test of the DenerveX System under the most stringent standards required by U.S. Food and Drug Administration (FDA) and other regulatory agencies.
 
“This latest testing of the DenerveX System is the largest living tissue population test to date. The results confirm that the DenerveX System delivers its intended treatment and that it supports the type of reimbursement that the company has already secured in its first targeted country, Germany,” said Patrick Kullmann, Medovex president and chief operating officer.
 
The GLP (Good Laboratory Practice) protocol testing consisted of a 12 porcine subject clinical evaluation of the DenerveX System at 0, 30- and 60-day time period post procedure. The total subject pool consisted of 144 treatments, of which 48 treatment sites were randomly selected and initially evaluated per the GLP.
 
Of the 48 evaluated treatments, 92 percent of the DenerveX System treatments reached their targeted facet joint treatment sites. Dorsal nerve roots and dorsal ganglia did not have evidence of neurodegeneration at the sites examined. No routinely examined organs had changes interpreted to be related to the study. All subjects survived the study to term absent complication.
 
“The DenerveX System delivered treatments that would be expected and desired as needed to provide longer term pain relief, and that would set up the DenerveX System and procedure as a new and unique therapy for facet joint syndrome,” said Martin Deeg, M.D., of Stuttgart, Germany, an advisory board member with experience using the DenerveX System.
 
Vik Kapoor, M.D., of Manchester, England, also an advisory board member and equally experienced with the DenerveX System, added, “The DenerveX System proved out in the data that it will fundamentally change the way Facet Joint Syndrome will be treated in the future.”
 
The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power Generator, both designed to be less invasive with faster recovery time than current surgical treatment options. It consists of two procedures combined into one device and is expected to provide for a longer lasting treatment solution while offering potential savings to the health care system. DenerveX is not yet commercially available.
 
DenerveX System is not yet CE marked or FDA cleared. A full evaluation of the test results continues. The results of the test have not yet been submitted to, or evaluated by, the notified body or FDA for consideration and comment.

“The DenerveX System represents a very new and creative approach in treating pain associated with the facet joint syndrome,” said Jarrett Gorlin, Medovex CEO. “Our future customers have commented their clear appreciation for our different approach in performing a new procedure by way of a posterior calsulectomy of the facet joint, compared to the less effective standard radio frequency ablation (Rhizotomy). This gives us cause for continued cautious optimism going forward.”
 
Medovex was formed to acquire and develop a diversified portfolio of potentially groundbreaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Atlanta, Ga.-based company’s first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome.